Congenica

Cambridge, 
United Kingdom
http://www.congenica.com
  • Booth: 831


Creating a new standard in genomic medicine

Profile

Congenica is the provider of the diagnostic decision support platform, Sapientia, and associated clinical services, which enable clinicians to interrogate the human genome to identify disease-causing variants. Sapientia is intuitive to use, supporting the routine diagnostic workflow whilst enabling clinicians to progress through cases more quickly, optimizing throughput of patients and diagnoses. Headquartered in Cambridge, UK, and with a footprint in the US and China, Congenica is borne out of pioneering research from the Wellcome Trust Sanger Institute and the NHS. Their product, Sapientia™ has been comprehensively evaluated in the UK 100,000 Genomes Project and is the chosen partner for use by the NHS in the national genomic medicine programme in the UK.


 Press Releases

  • Cambridge, United Kingdom – 1 April, 2019 – Congenica, the global diagnostic decision support platform provider, has announced that it now offers an on-premise deployment method in addition to cloud deployment for running its SapientiaTMplatform.

    This considerable technical achievement has been completed following feedback from customers from Government institutions, hospitals and private research organisations that they want locally operated decision support platforms that store and retain data locally. This is for reasons ranging from institutional preference through to local laws and guidelines related to management of patient data.

    Customers will now have greater choice when installing the SapientiaTM platform, enabling deployment either on a local infrastructure or the cloud. This allows for greater flexibility in how organisations control their platform and how the software is maintained, whilst still benefiting from the same functionally-rich platform capabilities.

    Both on-premise and cloud-based Software as a Service (SaaS) customers will also benefit from Congenica’s extensive investment into developing its active roadmap of innovative products throughout 2019 and beyond.

    Congenica’s commercial partner for the China market, Digital China Health (DCH), will be among the first to take advantage of the on-premise deployment. With the new on-premise deployment option, Congenica now offers a solution to meet the deployment needs of all organisations across China through DCH. Negotiations are already underway with major Chinese hospitals that require an on-premise solution and Congenica anticipates the flexible deployment model will help to further differentiate its offering and accelerate commercial progress in the global markets.

    Dr David Atkins, CEO of Congenica, commented: “This is a significant step forward for us. With a choice of deployment options, we now have a broader offering to address our customers’ and partners’ varying needs. We expect to be announcing commercial growth in the near future that is enabled by this engineering achievement.”

    To achieve automated application deployment, scaling, and management in an efficient and cost-effective manner, Congenica has taken advantage of the proven technology of Kubernetes, an open-source container orchestration system.

    Peter Fox, CTO of Congenica, stated: “Our new on-premise solution uses the proven and robust Kubernetes architecture and design. This simpler, faster and scalable deployment, with high resilience and availability, enables more secure and cost-effective software for our customers.

    “We believe this future-proofs Congenica’s platform for the next five to ten years, whilst also further investing in our SaaS cloud deployment.”

    This development is one of a series of recent advances in Congenica’s SapientiaTM technology, which also includes additional capacity and scalability functionality.

    Augusto Rendon, Director of Bioinformatics of Genomics England, commented: We are excited to hear of this latest development in Congenica’s technology. Congenica have been able to process a huge number of samples for the 100,000 Genomes Project, and routinely process several thousand samples a month for Genomics England.”